Rentokil got butchered yesterday but this FTSE stock could recover big time

Rentokil dragged the FTSE 100 down yesterday after news that it’s buying an American rival but here’s why this Fool thinks its recovery could be strong

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 was down yesterday for the fourth straight trading day. Unfortunately for the pest control company Rentokil Initial (LSE: RTO), it was front and centre of this decline. In fact, yesterday’s 12.3% decline represented the single worst trading day this company has seen in 13 years. The reason? Rentokil announced that it will be buying American rival, Terminix. So far, it’s not so much the acquisition that seems to have caused concern but rather the price tag on the deal that’s really bugging investors (pun intended). Reuters reported yesterday that Rentokil would pay $6.7bn (or £5.1bn) on the deal. That amounts to about $55 per share or a 47% premium compared to Terminix’s closing price on Monday. The irony is that while Rentokil stock is reeling, Terminix shares are up 18% since the news broke on Monday.

The underlying business

Rentokil has a solid underlying business model in its own right. It was already the world’s largest company in this industry. Nearly two-thirds of its revenues last year came from pest control and it has entrenched itself as the global leader in the industry. Since 2016 the company has acquired 228 companies, expanding its presence to 82 countries. From a financial perspective, what jumps out to me is that revenues that have been consistently growing over the past few years. This is backed by very chunky gross profits that are consistently either over or close to 80%. The bottom line could use a bit of a boost but with revenues growing by 14.5% in the last quarter, I’m confident in the ability of this company to continue to grow and drive up net earnings. There’s simply no FTSE 100 comparison due to the niche and scale on which this company operates.

A creepy-crawly killing FSTE conglomerate

I think that, while a 47% premium is undoubtedly quite hefty, what the market is failing to price in is all the advantages of this merger. With $2bn in revenue last year, a presence in 47 US states and a reputation as the second-largest company in the US pest control market, Terminix is a premium company. To get premium companies, you often have to pay a premium price. This deal will entrench Rentokil as the global leader. This unfettered access to the US market is coming at a time when the $22bn global pest control industry is growing rapidly. The onset of the pandemic, as well as a growing middle-class population, means that demand will continue to grow.

Last month Rentokil stated that labour shortages and Covid-19 related medical bills are driving up costs so this must be factored in. Russ Mould, investment director at AJ Bell, also noted that the deal could attract the attention of antitrust regulators in the US, which could present challenges for the company going forward. So, while I don’t think it will be smooth sailing, I think that this is a safe pick for my portfolio with loads of potential upside. Currently trading at 40 times earnings, it’s not the cheapest FTSE 100 stock right now but definitely one that I will be keeping on my radar.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stephen Bhasera has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 FTSE stocks I wouldn’t ‘Sell in May’

If the strategy had any merit in the past, I see no compelling evidence it's a smart idea today. Here…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Down 21% and yielding 10%, is this income stock a top contrarian buy now?

Despite its falling share price, this Fool reckons he's found an income stock that could be worth taking a closer…

Read more »

Investing Articles

The Meta share price falls 10% on weak Q2 guidance — should investors consider buying?

The Meta Platforms' share price is down 10% after the company reported Q1 earnings per share growth of 117%. Does…

Read more »

Investing Articles

This FTSE 250 defence stock looks like a hidden growth gem to me

With countries hiking defence spending as the world grows more insecure, this FTSE 250 firm has seen surging orders and…

Read more »